SCYNEXIS Revenue and Competitors
Estimated Revenue & Valuation
- SCYNEXIS's estimated annual revenue is currently $14.7M per year.
- SCYNEXIS's estimated revenue per employee is $216,544
- SCYNEXIS's total funding is $206.4M.
Employee Data
- SCYNEXIS has 68 Employees.
- SCYNEXIS grew their employee count by -23% last year.
SCYNEXIS Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $10.9M | 70 | 0% | N/A | N/A |
#2 | $0.9M | 6 | -14% | N/A | N/A |
#3 | $11.9M | 77 | -6% | N/A | N/A |
#4 | $106.8M | 492 | 23% | N/A | N/A |
#5 | $1.4M | 9 | 29% | N/A | N/A |
#6 | $0.9M | 6 | 200% | N/A | N/A |
#7 | $14.7M | 68 | -23% | $206.4M | N/A |
#8 | $492.2M | 1461 | 18% | $568M | N/A |
#9 | $2.5M | 16 | 0% | N/A | N/A |
#10 | $4.5M | 29 | 7% | N/A | N/A |
What Is SCYNEXIS?
SCYNEXIS™ provides a full range of synthesis chemistry services to the life sciences industry, From Concept To Clinic™. We offer novel hit generation compounds, hit explosion, lead optimization and radiochemistry services as well as the production of clinical samples in our GMP facility. Every day, SCYNEXIS is demonstrating that our people and technology meet the challenges – and even reshape – today’s pharmaceutical discovery process. The result: our customers are receiving unparalleled speed and efficiency that revolutionize the limits imposed on today’s discovery chemistry lab. SCYNEXIS is increasing the productivity and speed of the pharmaceutical discovery process by removing the boundaries of the chemistry lab. By utilizing our patented MEDCHEM-FACTORY™ process and other proprietary technology platforms, SCYNEXIS is quickly emerging as a company with special expertise in the areas of hit explosion and lead optimization. Harnessing technology in ways never seen before in discovery labs, we are uniquely positioned to meet the specific needs of our customers by providing targeted, and timely, expertise that is tailored to individual projects.
keywords:Healthcare$206.4M
Total Funding
68
Number of Employees
$14.7M
Revenue (est)
-23%
Employee Growth %
N/A
Valuation
N/A
Accelerator
SCYNEXIS News
Ongoing FURI and CARES studies are a key component of the SCYNEXIS strategy to build ibrexafungerp into a broad antifungal franchise. SCYNEXIS...
Scynexis hit the market eight months ago with Brexafemme, a long-awaited upgrade in the treatment of vaginal yeast infection. Now the New Jersey drugmaker...
The antifungal work at Scynexis is not abating. Looking to expand beyond its initial June 2021 nod for treating vaginal yeast infection,...
JERSEY CITY, N.J. - SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, announced that the U.S. Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets), ...
JERSEY CITY, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the sale of its 6.0% Senior Convertible Notes due 2026 for an agg ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $13.5M | 68 | 10% | N/A |
#2 | $17M | 70 | 35% | N/A |
#3 | $7.5M | 71 | 4% | N/A |
#4 | $14.1M | 71 | -4% | N/A |
#5 | $3.5M | 71 | 13% | N/A |
SCYNEXIS Executives
Name | Title |
---|---|
Ivor Macleod | Chief Financial Officer |
David Angulo | Chief Medical Officer |
Christine Coyne | Chief Commercial Officer, SCYNEXIS |
Marco Taglietti | President & Chief Executive Officer |
Lawrence Hoffman | Interim Chief Financial Officer |
Nkechi Azie | Vice President, Clinical Development and Medical Affairs |
Rajeshwar Motheram | Senior Vice President, Pharmaceutical Development And Supply Chain |
Richard Sledd | Vice President Marketing and Sales (interim CCO) |
Glen Park | Vice President, Regulatory Affairs and Quality Assurance |
Marco Taglietti | President & Chief Executive Officer |
Nkechi Azie | Vice President Clinical Development and Medical Affairs |